Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Factor Xa inhibitors developed by Boehringer Mannheim researchers

June 30, 1998

RPR acquires worldwide rights to Novartis anticoagulant

June 29, 1998

Schering-Plough initiates phase I with oral antithrombotic

June 25, 1998

BioChem Pharma describes lactams for thrombotic disorders

June 23, 1998

Eisai launches monteplase in first market

June 16, 1998

Bayer seeks FDA approval for improved second-generation hemophilia A product

June 12, 1998

Targeted NO donor enhances the activity of aspirin and heparin in preventing embolization

June 8, 1998

Avigen and Cell Genesys report success with gene therapy of hemophilia B

June 2, 1998

Emisphere Technologies begins phase II trial with oral heparin

June 1, 1998

Integrilin launched in first market today

June 1, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.